Guadecitabine
- Generic Name
- Guadecitabine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H24N9O10P
- CAS Number
- 929901-49-5
- Unique Ingredient Identifier
- 2KT4YN1DP7
- Background
Guadecitabine is under investigation for the treatment of Previously Treated Metastatic Colorectal Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Combination Study of Guadecitabine/ASTX727 and Pembrolizumab
- Conditions
- Interventions
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 34
- Registration Number
- NCT02998567
- Locations
- 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇬🇧UCLH, London, United Kingdom
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 33
- Registration Number
- NCT02935361
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 302
- Registration Number
- NCT02920008
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇸🇪Sahlgrenska University Hospital, Göteborg, Sweden
🇬🇧Heart of England NHS Foundation Trust - Heartlands Hospital, Birmingham, United Kingdom
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
- Conditions
- Interventions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Astex Pharmaceuticals, Inc.
- Target Recruit Count
- 417
- Registration Number
- NCT02907359
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- First Posted Date
- 2016-09-15
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 45
- Registration Number
- NCT02901899
- Locations
- 🇺🇸
The University of Chicago Medicine, Chicago, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT02892318
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸City of Hope, Duarte, California, United States
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT02684162
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 103
- Registration Number
- NCT02131597
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT02096055
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.